US approves ‘‘bitcoin lite’’ ETFs
The US financial regulator has begun approving bitcoin-themed exchange-traded funds, but with important caveats.
US regulators are still on the fence about cryptocurrencies. The US Securities and Exchange Commission (SEC) has begun to approve bitcoin-themed exchange-traded funds (ETFs), but with important caveats. Last week the SEC gave the nod to the Volt Crypto Industry Revolution and Tech ETF, says Hassan Maishera on FXEmpire. The ETF will offer investors exposure to some of the leading crypto firms on the market, such as Nasdaq-listed MicroStrategy. But the SEC has still yet to approve any cryptocurrency ETF “that seeks to directly track the performance of bitcoin”.
Investors use ETFs to track the performance of assets such as gold or equities, says Nathan Reiff on Investopedia. For all the hype, bitcoin remains difficult to invest in, requiring investors to turn to specialised exchanges and deal with “complex storage and security procedures”. A bitcoin ETF would allow a much larger pool of investors to buy bitcoin in the same way and on the same platforms where they trade stocks.
The approval of “bitcoin lite” ETFs such as Volt is a “sop” to investors, says Steve Johnson in the Financial Times. US regulators are still refusing to approve any ETFs “that invest in the cryptocurrency itself”, even though similar vehicles have already been launched in Canada and parts of Europe. SEC chair, Gary Gensler, has called cryptocurrencies a “wild west” and an “asset class…rife with fraud, scams and abuse”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
8 of the best converted properties for sale now
The best converted properties for sale – from an apartment in the former Hartley’s Jam factory on London’s Southbank, to a converted 18th-century mill in Itteringham, Norfolk
-
How taking a two-year career break could leave a £26k hole in your pension
Career breaks are increasingly common but it is important to take steps to protect your pension, as gaps compound over time
-
Will Comstock crash – or soar?
Opinion The upside for Comstock, a solar panel-recycling and biomass-refining group, dwarfs the downside, says Dominic Frisby.
-
'As AGMs go digital, firms must offer a new form of scrutiny for shareholders'
Opinion Technology has rendered big AGM meet-ups obsolete, but the board still needs to be held to account, says Matthew Lynn
-
Unilever braces for inflation amid tariff uncertainty – what does it mean for investors?
Consumer-goods giant Unilever has made steady progress simplifying its operations. Will tariffs now cause turbulence?
-
Two ways to tap into monopoly profits from airports
Most investors can’t get their hands on airports. Here are two ways you can
-
Fat profits: should you invest in weight-loss drugs?
The latest weight-loss treatments could transform public health and the world economy. Should you invest?
-
How investors could profit from Ramsden Holdings' four-part growth strategy
Ramsdens Holdings offers a diversified set of financial and retail services and a juicy yield, says Dr Michael Tubbs
-
How to invest in the booming insurance market
The insurance sector is experiencing rapid growth after years of stagnation. Smart investors should buy in now, says Rupert Hargreaves
-
Out of America's shadow: Why Trump's tariff chaos may be good for non-US stocks
Opinion Upending global investment and trade could benefit other countries at the expense of the US market, says Cris Sholto Heaton